Ronald Yanagihara

2.9k total citations · 2 hit papers
17 papers, 1.7k citations indexed

About

Ronald Yanagihara is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Ronald Yanagihara has authored 17 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Oncology, 7 papers in Pulmonary and Respiratory Medicine and 4 papers in Surgery. Recurrent topics in Ronald Yanagihara's work include Lung Cancer Treatments and Mutations (6 papers), Bone health and treatments (4 papers) and Colorectal Cancer Treatments and Studies (3 papers). Ronald Yanagihara is often cited by papers focused on Lung Cancer Treatments and Mutations (6 papers), Bone health and treatments (4 papers) and Colorectal Cancer Treatments and Studies (3 papers). Ronald Yanagihara collaborates with scholars based in United States, Poland and Australia. Ronald Yanagihara's co-authors include Lee S. Rosen, David Gordon, Vera Hirsh, Ming Zheng, Gladys Urbanowitz, Paul de Souza, Maciej Krzakowski, Marek Pawlicki, Dirk J. Reitsma and John J. Seaman and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and The Oncologist.

In The Last Decade

Ronald Yanagihara

17 papers receiving 1.6k citations

Hit Papers

Zoledronic Acid Versus Placebo in the Treatment of Skelet... 2003 2026 2010 2018 2003 2004 100 200 300 400 500
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Zoledronic Acid Versus Placebo in the Treatment of Skeletal Metastases in Patients With Lung Cancer and Other Solid Tumors: A Phase III, Double-Blind, Randomized Trial—The Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group
    2003 557 citations Lee S. Rosen, David Gordon et al. Journal of Clinical Oncology profile →
  2. Long‐term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors
    2004 507 citations Lee S. Rosen, David Gordon et al. Cancer profile →

Peers

Ronald Yanagihara
Lois Brafman United States
Tiziana Campa Italy
B. Jandolo Italy
Rikushi Morita Japan
Amandeep Kaur India
Kai-Hua Chen China
C. E. Fiore Italy
Alexander T. Faje United States
Martin Halle Sweden
Riitta Tähtelä Finland
Lois Brafman United States
Ronald Yanagihara
Citations per year, relative to Ronald Yanagihara Ronald Yanagihara (= 1×) peers Lois Brafman

Countries citing papers authored by Ronald Yanagihara

Since Specialization
Citations

This map shows the geographic impact of Ronald Yanagihara's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ronald Yanagihara with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ronald Yanagihara more than expected).

Fields of papers citing papers by Ronald Yanagihara

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ronald Yanagihara. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ronald Yanagihara. The network helps show where Ronald Yanagihara may publish in the future.

Co-authorship network of co-authors of Ronald Yanagihara

This figure shows the co-authorship network connecting the top 25 collaborators of Ronald Yanagihara. A scholar is included among the top collaborators of Ronald Yanagihara based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ronald Yanagihara. Ronald Yanagihara is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
Argiris, Athanassios, Jieling Miao, Mihaela Cristea, et al.. (2021). A Dose-finding Study Followed by a Phase II Randomized, Placebo-controlled Trial of Chemoradiotherapy With or Without Veliparib in Stage III Non–small-cell Lung Cancer: SWOG 1206 (8811). Clinical Lung Cancer. 22(4). 313–323.e1. 17 indexed citations
2.
Nagasaka, Misako, et al.. (2020). STRN-ALK, A Novel In-Frame Fusion With Response to Alectinib. JTO Clinical and Research Reports. 2(2). 100125–100125. 8 indexed citations
3.
Percent, Ivor, Craig H. Reynolds, Kartik Konduri, et al.. (2020). Phase III trial of sitravatinib plus nivolumab vs. docetaxel for treatment of NSCLC after platinum-based chemotherapy and immunotherapy (SAPPHIRE).. Journal of Clinical Oncology. 38(15_suppl). TPS9635–TPS9635. 12 indexed citations
4.
Argiris, Athanassios, Mihaela Cristea, Allen Chen, et al.. (2019). S1206: A dose-finding study followed by a phase II randomized placebo-controlled trial of chemoradiotherapy (CRT) with or without veliparib in stage III non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology. 37(15_suppl). 8523–8523. 3 indexed citations
5.
Smith, C., Ronald Yanagihara, Marek Spaczyński, et al.. (2015). Pharmacokinetics, safety, and efficacy of APF530 (extended-release granisetron) in patients receiving moderately or highly emetogenic chemotherapy: results of two Phase II trials. Cancer Management and Research. 7. 83–83. 14 indexed citations
6.
Gabrail, Nashat, et al.. (2013). Pharmacokinetics (PK), tolerability, and efficacy of APF530 in patients receiving moderately (MEC) and highly (HEC) emetogenic chemotherapy: Phase II trial results.. Journal of Clinical Oncology. 31(15_suppl). e20518–e20518. 2 indexed citations
7.
Portenoy, Russell K., Silvia Allende‐Pérez, Ronald Yanagihara, et al.. (2012). Nabiximols for Opioid-Treated Cancer Patients With Poorly-Controlled Chronic Pain: A Randomized, Placebo-Controlled, Graded-Dose Trial. Journal of Pain. 13(5). 438–449. 291 indexed citations
8.
Spira, Alexander I., Nicholas Iannotti, Michael A. Savin, et al.. (2011). A Phase II Study of Eribulin Mesylate (E7389) in Patients With Advanced, Previously Treated Non–Small-Cell Lung Cancer. Clinical Lung Cancer. 13(1). 31–38. 26 indexed citations
9.
Pietanza, M. Catherine, Thomas J. Lynch, Primo N. Lara, et al.. (2011). XL647—A Multitargeted Tyrosine Kinase Inhibitor: Results of a Phase II Study in Subjects with Non-small Cell Lung Cancer Who Have Progressed after Responding to Treatment with Either Gefitinib or Erlotinib. Journal of Thoracic Oncology. 7(1). 219–226. 45 indexed citations
10.
Haller, Daniel G., Deepti Singh, Al B. Benson, et al.. (2006). Extended safety and efficacy data on S‐1 plus cisplatin in patients with untreated, advanced gastric carcinoma in a multicenter phase II study. Cancer. 109(1). 33–40. 45 indexed citations
11.
Ajani, Jaffer A., D. A. Singh, Daniel G. Haller, et al.. (2006). Multicenter Phase II Trial of S-1 Plus Cisplatin in Patients With Untreated Advanced Gastric or Gastroesophageal Junction Adenocarcinoma. Journal of Clinical Oncology. 24(4). 663–667. 81 indexed citations
12.
Rosen, Lee S., David Gordon, N. Simon Tchekmedyian, et al.. (2004). Long‐term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors. Cancer. 100(12). 2613–2621. 507 indexed citations breakdown →
13.
Vogel, Charles L., Ronald Yanagihara, Frederick M. Schnell, et al.. (2004). Safety and Pain Palliation of Zoledronic Acid in Patients with Breast Cancer, Prostate Cancer, or Multiple Myeloma Who Previously Received Bisphosphonate Therapy. The Oncologist. 9(6). 687–695. 63 indexed citations
14.
Rosen, Lee S., David Gordon, Simon Tchekmedyian, et al.. (2003). Zoledronic Acid Versus Placebo in the Treatment of Skeletal Metastases in Patients With Lung Cancer and Other Solid Tumors: A Phase III, Double-Blind, Randomized Trial—The Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group. Journal of Clinical Oncology. 21(16). 3150–3157. 557 indexed citations breakdown →
15.
16.
Yanagihara, Ronald, et al.. (1998). IgM myeloma: Case report with immunophenotypic profile. American Journal of Hematology. 59(4). 302–308. 16 indexed citations
17.
Forman, Walter B., et al.. (1993). A novel morphine sulphate preparation: clinical trial of a controlled-release morphine suspension in cancer pain. Palliative Medicine. 7(4). 301–306. 22 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Lois Brafman Breakdown of academic impact, for papers by Tiziana Campa Breakdown of academic impact, for papers by B. Jandolo Breakdown of academic impact, for papers by Rikushi Morita Breakdown of academic impact, for papers by Amandeep Kaur Breakdown of academic impact, for papers by Kai-Hua Chen Breakdown of academic impact, for papers by C. E. Fiore Breakdown of academic impact, for papers by Alexander T. Faje Breakdown of academic impact, for papers by Martin Halle Breakdown of academic impact, for papers by Riitta Tähtelä
Rankless by CCL
2026